Detail akcie Dyadic Intl online

Business Summary: Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Dyadic International Inc revenues decreased 6% to $2.5M. Net loss increased 36% to $5.8M. Revenues reflect Research and Development Revenue decrease of 40% to $747K. Higher net loss reflects United states-Operating segment loss increase of 29% to $5.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.15 to -$0.18.